NeuroOne Revenue Jumps 105 Percent in Q3

Key Points

• Earnings per share (GAAP) improved to $(0.03) in Q3 FY2025, beating the analyst estimate of $(0.05).

• Revenue (GAAP) climbed 105% year over year to $1.7 million in Q3 FY2025, missing analyst expectations of $1.82 million.

• Product gross margin expanded to 53.9%, up from 34.1% in Q3 FY2024.

• These 10 stocks could mint the next wave of millionaires ›

NeuroOne Medical Technologies (NASDAQ:NMTC), a med-tech company specializing in advanced thin film electrode and ablation systems for neurological disorders, reported Q3 FY2025 results on August 14, 2025. The earnings release showcased a material improvement in profitability, with earnings per share (GAAP) narrowing to $(0.03), outpacing analyst forecasts of $(0.05). The company delivered $1.7 million in GAAP revenue, representing 105% growth over the prior-year period, though falling short of the $1.82 million consensus estimate. Robust cost discipline and significant gross margin gains highlighted the quarter, while the revenue miss pointed to uneven adoption, as GAAP revenue was $1.7 million, 6.4% below the analysts' estimate of $1.82 million. Overall, the period reflected notable progress on both financial and operational fronts, but near-term sales trajectory remains a key area of focus for observers.

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report.

Company Overview and Recent Focus

NeuroOne Medical Technologies develops advanced medical devices used in the diagnosis and treatment of neurological conditions, such as epilepsy and Parkinson’s disease. Its main offerings include thin film electrodes for continuous brain monitoring (cEEG and sEEG devices) and the OneRF ablation system, which enables both diagnostic monitoring and minimally invasive surgical procedures using a single implant. The technology aims for higher precision, smaller device size, and less invasive treatments.

A central focus in recent quarters has been expanding commercial sales through strategic partnerships. The distribution alliance with Zimmer Biomet gives NeuroOne access to broader U.S. hospital networks, accelerating adoption and market penetration for its devices. Regulatory progress, continued innovation in electrode and ablation systems, and pipeline expansion into new treatment areas—such as drug delivery and pain management—are seen as key success drivers. Gaining U.S. Food and Drug Administration (FDA) clearances, controlling costs, and demonstrating strong patient outcomes all remain top priorities.

Quarterly Financial and Operational Developments

The most recent quarter was marked by rapid revenue growth, with product sales (GAAP) more than doubling (up 105%) compared to the prior-year period. While this pace signals traction, revenue (GAAP) fell 6.4% short of consensus estimates Nearly all revenue continued to flow through the partnership with Zimmer Biomet in Q2 FY2025, so any changes in that channel remain highly impactful.

Gross margin, a key profitability measure calculated as gross profit divided by sales, jumped to 53.9%, up nearly 20 percentage points from a year ago and exceeding earlier forecasts.

Total operating expenses fell to $2.8 million, reflecting tighter spending, with selling, general and administrative (SG&A) costs dropping 14%. Research and development (R&D) spending held steady as the company balanced innovation with fiscal discipline. The narrowing net loss to $1.5 million (GAAP) underscores these efficiency gains, achieved even as NeuroOne ramps up sales and marketing efforts. The company also completed an $8.2 million capital raise in April 2025, boosting cash reserves and extending its funding runway through at least fiscal 2026.

On the clinical and regulatory side, the company advanced several milestones. The first patient treated with the OneRF ablation system surpassed one year of seizure freedom as of June 2025. The FDA submission for a trigeminal nerve ablation product—used for facial pain management—was filed ahead of schedule in Q2 FY2025, creating a path for potential new revenue by late calendar 2025 if cleared. Additionally, the drug delivery program using sEEG technology saw its first order from a large pharmaceutical partner, signaling early adoption in a new market. International efforts remain at the preparation stage, as the company began securing ISO13485 certification, necessary for non-U.S. commercial launches. The patent portfolio also expanded, strengthening the firm’s intellectual property position.

Looking Ahead and Guidance

Management reaffirmed FY2025 product revenue guidance of $8.0 million to $10.0 million, excluding a $3.0 million upfront license payment from Zimmer Biomet. This represents projected annual growth of 132% to 190% for FY2025 over FY2024. Product gross margin expectations were raised to 50%–53% for FY2025, up from earlier projections,

For future quarters, key metrics for investors include quarterly sales pace, commercialization progress outside the United States, and timelines for upcoming FDA clearance decisions. Management specifically cited a funding runway through at least the end of fiscal 2026, reducing short-term liquidity concerns. Ex-U.S. launches and additional strategic partnerships, if secured, could further alter the company’s growth profile.

Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,069%* — a market-crushing outperformance compared to 184% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

See the stocks »

*Stock Advisor returns as of August 13, 2025

JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.